Current Guidelines for TB Diagnosis and Treatment in Adults and Children
The most recent 2025 ATS/CDC/ERS/IDSA guidelines recommend shorter, all-oral treatment regimens: 4-month therapy for both adults with drug-susceptible pulmonary TB and children aged 3 months-16 years with nonsevere TB, replacing the traditional 6-month regimen 1.
Diagnosis
Adults and Adolescents
For suspected pulmonary TB, obtain respiratory specimens for both molecular testing (Xpert MTB/RIF or equivalent NAAT) and mycobacterial culture with drug susceptibility testing. The FDA-approved Xpert MTB/RIF provides simultaneous TB diagnosis and rifampin resistance detection 2.
- Collect sputum specimens on 3 consecutive days for optimal yield
- Molecular testing provides rapid results (hours) while culture remains essential for drug susceptibility testing
- Culture is mandatory even with positive molecular tests to guide treatment if resistance develops
Children
Mycobacterial culture of respiratory specimens is recommended for all children with suspected pulmonary TB 2. However, microbiological confirmation may be unnecessary for children with uncomplicated pulmonary TB identified through recent contact investigation if the source case has documented drug-susceptible disease 2.
Specimen collection methods by yield:
- Gastric aspirates: 40-50% yield overall, up to 90% in infants; collect on 3 consecutive mornings after overnight fast
- Induced sputum/nasopharyngeal aspiration: 20-30% yield
- Bronchoalveolar lavage: 10-22% yield
Critical caveat: Always obtain cultures for infants, immunocompromised children, those with extensive/disseminated/extrapulmonary disease, exposure to multiple source cases, or any risk of drug resistance 2.
Diagnostic Technologies (2025 Updates)
Digital chest radiography with computer-aided detection is now a core WHO-recommended screening and triage tool 3. Molecular diagnostics have expanded to include:
- Low-complexity automated NAATs (Xpert MTB/RIF Ultra, Truenat)
- Novel specimen types including tongue swabs for sputum-scarce patients
- Stool, gastric aspirate, and nasopharyngeal samples for children 3
Treatment
Drug-Susceptible TB
Adults with Pulmonary TB
A novel 4-month regimen is now recommended over the traditional 6-month regimen 1. While the specific regimen details are referenced in dosing tables, this represents a major shift toward shorter therapy.
Children (3 months to 16 years)
For nonsevere TB without MDR/RR-TB suspicion: Use 4-month regimen of 2HRZ(E)/2HR rather than 6-month regimen of 2HRZ(E)/4HR (strong recommendation, moderate certainty) 1.
Dosing principles:
- Use actual body weight
- Administer 7 days/week with food
- Directly observed therapy (DOT) 5 of 7 days per week
- Always give pyridoxine (vitamin B6) 25-50 mg/day with isoniazid 1
Ethambutol consideration: Some clinicians exclude ethambutol for HIV-uninfected children with no prior TB treatment, living in low DR-TB prevalence areas, and no exposure to high-prevalence individuals. However, the American Academy of Pediatrics recommends including ethambutol in the intensive phase for most children 1.
Drug-Resistant TB
Rifampin-Resistant, Fluoroquinolone-Susceptible TB (Ages ≥14 and Adults)
Use 6-month BPaLM regimen rather than 15+ month regimens (strong recommendation, very low certainty) 1:
- Bedaquiline: 400 mg daily × 2 weeks, then 200 mg 3×/week × 24 weeks
- Pretomanid: 200 mg daily × 26 weeks
- Linezolid: 600 mg daily × 26 weeks
- Moxifloxacin: 400 mg daily × 26 weeks
Administer 7 days/week with food, avoiding milk, antacids, or cationic items; DOT 5 of 7 days weekly 1.
Rifampin-Resistant with Fluoroquinolone Resistance/Intolerance (Ages ≥14 and Adults)
For patients with no previous bedaquiline/linezolid exposure (or <1 month exposure): Use 6-month BPaL regimen rather than 15+ month regimens (strong recommendation, very low certainty) 1.
This consists of bedaquiline, pretomanid, and linezolid without moxifloxacin.
Key Implementation Points
Critical Pitfalls to Avoid
Do not skip cultures in children even with known source case susceptibility if the child has severe disease, immunocompromise, or any drug resistance risk 2
Do not use line probe assays on non-respiratory specimens - insufficient validation 2
Ensure rifampin resistance testing - Xpert MTB/RIF automatically provides this regardless of patient risk 2
Do not forget pyridoxine with isoniazid to prevent peripheral neuropathy 1
Quality of Life Considerations
The shift to shorter regimens (4-6 months vs 6-18+ months) dramatically improves:
- Treatment adherence
- Reduced isolation periods
- Decreased medication burden and adverse effects
- Earlier return to normal activities
These all-oral regimens eliminate injectable agents previously required for drug-resistant TB, substantially improving tolerability 1, 4, 5.
Emerging Evidence
The TB drug pipeline in 2026 is more robust than any time since rifampin's introduction, with DprE1 inhibitors, next-generation oxazolidinones, and long-acting formulations in late-stage trials 5. Host-directed therapies are advancing as adjunctive strategies to reduce inflammation-mediated tissue damage, though remain investigational 5.